BioSpace

Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.

Por BioSpace

1 minuto de lectura
Compartir
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas